GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.

SQZ Biotechnologies, a US-based cellular vaccine developer spun out of Massachusetts Institute of Technology, closed a $65m series D round on Monday that included GV and Illumina Ventures, respective investment subsidiaries of internet technology conglomerate Alphabet and genomics technology producer Illumina.
The round was led by Singaporean government-owned investment firm Temasek and also featured NanoDimension, Polaris Partners, an unnamed US-based fund and JDRF T1D Fund, which is managed by diabetes-focused charity JRDF.
Founded in 2013, SQZ is working…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in